Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Blincyto® (blinatumomab) for the Treatment of B-cell Precursor Acute Lymphoblastic Leukaemia

Drug Name

Blincyto® (Blinatumomab / MT103)

Company / Licensee

Amgen

Therapy Class

Monoclonal antibody

Product Description

Bispecific CD19-directed CD3 T-cell engager

Current Indication

B-cell precursor acute lymphoblastic leukemia (ALL)

Market Sector

Oncology

Development Status

Approved in the US and Europe
Expand

Go Top